247 related articles for article (PubMed ID: 24964808)
1. Immunogenicity of a synthetic vaccine based on Plasmodium vivax Duffy binding protein region II.
Ntumngia FB; Barnes SJ; McHenry AM; George MT; Schloegel J; Adams JH
Clin Vaccine Immunol; 2014 Sep; 21(9):1215-23. PubMed ID: 24964808
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity of single versus mixed allele vaccines of Plasmodium vivax Duffy binding protein region II.
Ntumngia FB; Schloegel J; McHenry AM; Barnes SJ; George MT; Kennedy S; Adams JH
Vaccine; 2013 Sep; 31(40):4382-8. PubMed ID: 23916294
[TBL] [Abstract][Full Text] [Related]
3. Design and immunogenicity of a novel synthetic antigen based on the ligand domain of the Plasmodium vivax duffy binding protein.
Ntumngia FB; Adams JH
Clin Vaccine Immunol; 2012 Jan; 19(1):30-6. PubMed ID: 22116684
[TBL] [Abstract][Full Text] [Related]
4. Identification of an Immunogenic Broadly Inhibitory Surface Epitope of the Plasmodium vivax Duffy Binding Protein Ligand Domain.
George MT; Schloegel JL; Ntumngia FB; Barnes SJ; King CL; Casey JL; Foley M; Adams JH
mSphere; 2019 May; 4(3):. PubMed ID: 31092602
[TBL] [Abstract][Full Text] [Related]
5. Dynamics of IgM and IgG responses to the next generation of engineered Duffy binding protein II immunogen: Strain-specific and strain-transcending immune responses over a nine-year period.
Medeiros CMP; Moreira EUM; Pires CV; Torres LM; Guimarães LFF; Alves JRS; Lima BAS; Fontes CJF; Costa HL; Brito CFA; Sousa TN; Ntumngia FB; Adams JH; Kano FS; Carvalho LH
PLoS One; 2020; 15(5):e0232786. PubMed ID: 32379804
[TBL] [Abstract][Full Text] [Related]
6. Structural analysis of the synthetic Duffy Binding Protein (DBP) antigen DEKnull relevant for Plasmodium vivax malaria vaccine design.
Chen E; Salinas ND; Ntumngia FB; Adams JH; Tolia NH
PLoS Negl Trop Dis; 2015 Mar; 9(3):e0003644. PubMed ID: 25793371
[TBL] [Abstract][Full Text] [Related]
7. Strain-Transcending Inhibitory Antibodies against Homologous and Heterologous Strains of Duffy Binding Protein region II.
Wongkidakarn S; McHenry AM; Sattabongkot J; Adams JH; Chootong P
PLoS One; 2016; 11(5):e0154577. PubMed ID: 27145131
[TBL] [Abstract][Full Text] [Related]
8. Finding the sweet spots of inhibition: understanding the targets of a functional antibody against Plasmodium vivax Duffy binding protein.
Ntumngia FB; King CL; Adams JH
Int J Parasitol; 2012 Nov; 42(12):1055-62. PubMed ID: 23068913
[TBL] [Abstract][Full Text] [Related]
9. Targeting a Reticulocyte Binding Protein and Duffy Binding Protein to Inhibit Reticulocyte Invasion by Plasmodium vivax.
Gupta S; Singh S; Popovici J; Roesch C; Shakri AR; Guillotte-Blisnick M; Huon C; Menard D; Chitnis CE
Sci Rep; 2018 Jul; 8(1):10511. PubMed ID: 30002416
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity of Plasmodium vivax combination subunit vaccine formulated with human compatible adjuvants in mice.
Devi YS; Mukherjee P; Yazdani SS; Shakri AR; Mazumdar S; Pandey S; Chitnis CE; Chauhan VS
Vaccine; 2007 Jul; 25(28):5166-74. PubMed ID: 17544179
[TBL] [Abstract][Full Text] [Related]
11. Generation, characterization and immunogenicity of a novel chimeric recombinant protein based on Plasmodium vivax AMA-1 and MSP1
Rocha MV; Françoso KS; Lima LC; Camargo TM; Machado RLD; Costa FTM; Rénia L; Nosten F; Russell B; Rodrigues MM; Soares IS
Vaccine; 2017 Apr; 35(18):2463-2472. PubMed ID: 28341111
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and protective efficacy of recombinant vaccine based on the receptor-binding domain of the Plasmodium vivax Duffy binding protein in Aotus monkeys.
Arévalo-Herrera M; Castellanos A; Yazdani SS; Shakri AR; Chitnis CE; Dominik R; Herrera S
Am J Trop Med Hyg; 2005 Nov; 73(5 Suppl):25-31. PubMed ID: 16291763
[TBL] [Abstract][Full Text] [Related]
13. Multiplexed Microsphere-Based Flow Cytometric Assay to Assess Strain Transcending Antibodies to
Alves JRS; de Araújo FF; Pires CV; Teixeira-Carvalho A; Lima BAS; Torres LM; Ntumngia FB; Adams JH; Kano FS; Carvalho LH
Front Immunol; 2021; 12():704653. PubMed ID: 34675915
[TBL] [Abstract][Full Text] [Related]
14. The association of Duffy binding protein region II polymorphisms and its antigenicity in Plasmodium vivax isolates from Thailand.
Chootong P; McHenry AM; Ntumngia FB; Sattabongkot J; Adams JH
Parasitol Int; 2014 Dec; 63(6):858-64. PubMed ID: 25108177
[TBL] [Abstract][Full Text] [Related]
15. A Library of Plasmodium vivax Recombinant Merozoite Proteins Reveals New Vaccine Candidates and Protein-Protein Interactions.
Hostetler JB; Sharma S; Bartholdson SJ; Wright GJ; Fairhurst RM; Rayner JC
PLoS Negl Trop Dis; 2015 Dec; 9(12):e0004264. PubMed ID: 26701602
[TBL] [Abstract][Full Text] [Related]
16. An engineered vaccine of the Plasmodium vivax Duffy binding protein enhances induction of broadly neutralizing antibodies.
Ntumngia FB; Pires CV; Barnes SJ; George MT; Thomson-Luque R; Kano FS; Alves JRS; Urusova D; Pereira DB; Tolia NH; King CL; Carvalho LH; Adams JH
Sci Rep; 2017 Oct; 7(1):13779. PubMed ID: 29062081
[TBL] [Abstract][Full Text] [Related]
17. The Presence, Persistence and Functional Properties of Plasmodium vivax Duffy Binding Protein II Antibodies Are Influenced by HLA Class II Allelic Variants.
Kano FS; Souza-Silva FA; Torres LM; Lima BA; Sousa TN; Alves JR; Rocha RS; Fontes CJ; Sanchez BA; Adams JH; Brito CF; Pires DE; Ascher DB; Sell AM; Carvalho LH
PLoS Negl Trop Dis; 2016 Dec; 10(12):e0005177. PubMed ID: 27959918
[TBL] [Abstract][Full Text] [Related]
18. Production of recombinant PvDBPII, receptor binding domain of Plasmodium vivax Duffy binding protein, and evaluation of immunogenicity to identify an adjuvant formulation for vaccine development.
Bhardwaj R; Shakri AR; Hans D; Gupta P; Fernandez-Becerra C; Del Portillo HA; Pandey G; Chitnis CE
Protein Expr Purif; 2017 Aug; 136():52-57. PubMed ID: 26578115
[TBL] [Abstract][Full Text] [Related]
19. Murine immune responses to a Plasmodium vivax-derived chimeric recombinant protein expressed in Brassica napus.
Lee C; Kim HH; Choi KM; Chung KW; Choi YK; Jang MJ; Kim TS; Chung NJ; Rhie HG; Lee HS; Sohn Y; Kim H; Lee SJ; Lee HW
Malar J; 2011 Apr; 10():106. PubMed ID: 21529346
[TBL] [Abstract][Full Text] [Related]
20. Characterization of inhibitory anti-Duffy binding protein II immunity: approach to Plasmodium vivax vaccine development in Thailand.
Chootong P; Panichakul T; Permmongkol C; Barnes SJ; Udomsangpetch R; Adams JH
PLoS One; 2012; 7(4):e35769. PubMed ID: 22558221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
